The Column Group — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders.
BiotechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Executive Officer)Arnold Kriegstein(Director)
BoardRay Kelleher(Director)
Board seatPeter SvennilsonTim KutzkeyDavid Goeddel· per SEC Form D
Co-investorsBerkeley FrontierIaso VenturesYsios CapitalAlexandriaFidelity InvestmentsLYFE Capital+7 more
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtech
Co-investorsDCVC BioLux Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.